T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01376674|
Recruitment Status : Completed
First Posted : June 20, 2011
Last Update Posted : August 16, 2013
Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner.
In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken at different time points before during and after standard radiotherapy in patients with localised prostate cancer. The overall activity of the T-cell-system as well as tumor-specific T-cell-response are evaluated.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||22 participants|
|Official Title:||Changes of T-cell-immune-status During Curative Radiotherapy in Prostate Cancer|
|Study Start Date :||March 2011|
- T-cell-immunity in time-course [ Time Frame: During and 3-6 months after radiotherapy ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01376674
|Department of Radiation Oncology|
|Tuebingen, Germany, D-72076|
|Principal Investigator:||Cihan Gani, M.D.||University Hospital Tuebingen|
|Study Director:||Franziska Eckert, MD||University Hospital Tuebingen|